TargetBeta
BTK
Bruton tyrosine kinase · also ATK, XLA, PSCTK1, AGMX1 · Pleckstrin homology domain containing
25 programs in company-led studies act on BTK, from 20 companies: 12 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (20 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| acalabrutinibrule | AstraZeneca | phase 4 | 5522 running | – | NCIt |
| pirtobrutinibrule | Eli Lilly | phase 4 | 3012 running | – | NCIt |
| zanubrutinibrule | BeOne Medicines | phase 4 | 358 running | – | NCIt |
| ibrutinibrule | Johnson & Johnson | phase 4 | 786 running | – | NCIt |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 2713 running | – | NCIt |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 1512 running | – | NCIt |
| rilzabrutinibrule | Sanofi | phase 3 | 2311 running | – | NCIt |
| ritlecitinibrule | Pfizer | phase 3 | 428 running | BMX, ITK, JAK3, TEC, TXK | ChEMBL |
| nemtabrutinib | Merck | phase 3 | 167 running | – | the company's pipeline |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 127 running | LYN | NCIt |
| tacabrutidegrule | BeOne Medicines | phase 3 | 87 running | – | NCIt |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 186 running | – | a judged reading |
| tirabrutinibrule | Gilead Sciences | phase 3 | 134 running | – | NCIt |
| bexobrutidegrule | Nurix Therapeutics | phase 3 | 64 running | HSF4 | NCIt |
| BTK Inhibitor HMPL-760rule | HUTCHMED | phase 3 | 51 running | – | NCIt |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 200 running | – | NCIt |
| BTK Inhibitor TQB3702 | Sino Biopharmaceutical | phase 2 | 43 running | – | the company's pipeline |
| BTK Inhibitor TT-01488rule | TransThera Sciences (Nanjing) | phase 2 | 32 running | – | NCIt |
| poseltinibrule | Eli Lilly | phase 2 | 61 running | – | NCIt |
| EVER001rule | Everest Medicines (China) | phase 2 | 21 running | – | the studies' text |
| TQB3702 tablets+Chemotherapy regimen | Sino Biopharmaceutical | phase 2 | 11 running | – | the company's pipeline |
| JNJ-64264681rule | Johnson & Johnson | phase 1 | 41 running | – | NCIt |
| BTK Degrader ABBV-101rule | AbbVie | phase 1 | 21 running | – | NCIt |
| BTK Degrader APG-3288rule | Ascentage Pharma Group International | phase 1 | 11 running | – | NCIt |
| TQB3019 | Sino Biopharmaceutical | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Leukemia, Lymphocytic, Chronic, B-Cell, 10 programs
- Lymphoma, Large B-Cell, Diffuse, 7 programs
- Lymphoma, Mantle-Cell, 7 programs
- Lymphoma, B-Cell, 5 programs
- Lymphoma, Non-Hodgkin, 5 programs
- Arthritis, Rheumatoid, 4 programs
- Hematologic Neoplasms, 4 programs
- Lupus Erythematosus, Systemic, 4 programs
- Purpura, Thrombocytopenic, Idiopathic, 4 programs
- Chronic Urticaria, 3 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 23, 2026birelentinib · Dizal Pharmaceuticals · phase 3 · NCT07888569
- Nov 25, 2026rilzabrutinib · Sanofi · phase 3 · NCT07216079
- Nov 30, 2026tacabrutideg · BeOne Medicines · phase 3 · NCT07005713
- Dec 2026BTK Inhibitor TQB3702 · Sino Biopharmaceutical · phase 2 · NCT06859931
- Dec 2, 2026ritlecitinib · Pfizer · phase 3 · NCT07029711
- Dec 31, 2026zanubrutinib · BeOne Medicines · phase 4 · NCT04170283
- Dec 31, 2026ibrutinib · Johnson & Johnson · phase 4 · NCT01804686
- Dec 31, 2026poseltinib · Eli Lilly · phase 2 · NCT07114367
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.